AU
UK
CA
NZ
IND
US
Annovis Bio Strengthens Capital Position
MetaVia (NASDAQ: MTVA) received a vote of confidence fromWall Streetthis week as an analyst at H.C. Wainwright maintained a Buy rating on the stock with a $20.00 price target. The endorsement centres on DA-1726, the company's lead asset and its bid to carve out …
Onconetix, Inc. (NASDAQ: ONCO) has announced a significant corporate restructuring move that signals a dramatic strategic shift for the company. TheBoard of Directorshas approved a 1-for-10 reverse stock split of its common stock, set to take effect at market open on May 21, 2026. …
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced the commencement of a 12-week open-label Phase 2b extension study for Halneuron, its first-in-class non-opioid analgesic targeting chemotherapy-induced neuropathic pain. The extension follows a positive pre-planned interim analysis from the ongoing 4-week double-blinded Phase 2b study — a …
GeoVax Labs, Inc. (Nasdaq: GOVX) confirmed this week that it holds U.S. Patent No. 11,701,418, covering its Modified Vaccinia Ankara viral vector platform engineered to express Ebola virus glycoprotein and matrix protein. The patent protects a platform designed to generate noninfectious virus-like particles that …
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) found itself in the frustrating position familiar to many small-cap biotechs this week — announcing genuinely positive manufacturing and stability data only to watch its shares reverse earlier gains and trade lower by the close. The divergence between the …
Clearmind Medicine (NASDAQ: CMND) has announced a 1-for-10 reverse stock split effective May 21, 2026, joining a growing list of small-cap biotechs taking corrective action to maintain their Nasdaq listings in a challenging market environment. The company's outstanding shares will be reduced from approximately …
Relay Therapeutics (Nasdaq: RLAY) delivered encouraging early Phase 2 data this week that meaningfully advances the clinical case for zovegalisib in vascular anomalies — an underserved patient population with limited treatmentOptionsand significant unmet medical need. The results, drawn from the ReInspire study, offer the …
Lipocine Inc. (Nasdaq: LPCN) announced that Phase 3 clinical data for LPCN 1154 — its oral formulation of brexanolone — has been selected for both an oral and a poster presentation at the 2026 American Society of Clinical Psychopharmacology Annual Meeting, running May 26–29, …
Please wait processing your request...